Bupropion–Dextromethorphan Combination for Lower-Dose NMDA Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder, particularly in patients with renal impairment, concomitant CYP2D6 inhibitor use, CYP2D6 poor metabolizers, and those at risk of QT prolongation, face challenges such as dose adjustments, potential for dissociation, and QT interval prolongation, without addressing the need for effective NMDA receptor antagonism.
Innovation Solution
A combination therapy of 105 mg bupropion hydrochloride and 45 mg dextromethorphan hydrobromide, administered once or twice daily, tailored for specific patient populations to manage renal impairment, CYP2D6 metabolism, and QT risk, providing NMDA receptor antagonism without dissociation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of dextromethorphan are used to achieve effective NMDA receptor antagonism for treating major depressive disorder, then therapeutic efficacy is improved, but the risk of QT interval prolongation and dissociation increases
Solution Approach 1:
The patent combines dextromethorphan with bupropion in a fixed-dose formulation. Bupropion serves multiple functions: it inhibits CYP2D6 metabolism of dextromethorphan (allowing lower doses), provides additional antidepressant efficacy through norepinephrine and dopamine reuptake inhibition, and the combination achieves therapeutic effect at lower dextromethorphan doses that reduce QT prolongation risk
Solution Approach 2:
The patent establishes specific dosage parameters (15 mg to 45 mg dextromethorphan hydrobromide and 75 mg to 150 mg bupropion hydrochloride) that optimize therapeutic efficacy while minimizing QT prolongation risk. These parameter changes allow effective NMDA receptor antagonism without reaching doses associated with significant cardiac adverse events
2Reliability
If dextromethorphan is administered to achieve NMDA receptor antagonism, then antidepressant effect is improved, but dissociation occurs as a side effect
Solution Approach 1:
The combination of dextromethorphan and bupropion provides synergistic antidepressant effects. Bupropion's mechanism (norepinephrine and dopamine reuptake inhibition) complements dextromethorphan's NMDA antagonism, achieving effective antidepressant treatment through multiple mechanisms while allowing lower dextromethorphan doses that reduce dissociation risk
3Reliability
If dose adjustments are made for patients with renal impairment or CYP2D6 poor metabolizers, then safety is improved, but treatment complexity increases
Solution Approach 1:
The fixed-dose combination formulation simplifies treatment by providing pre-determined dosing ratios of dextromethorphan and bupropion. This eliminates the need for clinicians to calculate and adjust individual doses based on renal function or CYP2D6 status, reducing treatment complexity while maintaining safety through the established dosing range
Solution Approach 2:
The combination formulation serves multiple patient populations (including renal impairment and CYP2D6 poor metabolizers) with a single dosing regimen. The bupropion component compensates for reduced dextromethorphan metabolism in CYP2D6 poor metabolizers, providing universal applicability across different patient groups
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively treats major depressive disorder with reduced risk of QT prolongation and dissociation, achieving steady-state plasma concentrations within 8 days, suitable for various patient groups including those with renal impairment and CYP2D6 poor metabolizers.
Implementation Method 1
the dextromethorphan acts as an uncompetitive antagonist of the NMDA receptor
Implementation Method 2
the dextromethorphan acts as an uncompetitive antagonist of the NMDA receptor and a sigma-1 receptor agonist
Data Source
AI summary
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.